Drug Treatment of Dyslipoproteinemia

Alderman, 1989, Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio, Am J Cardiol, 64, 725, 10.1016/0002-9149(89)90754-6 Altschul, 1955, Influence of nicotinic acid on serum cholesterol in man, Arch Biochem Biophys, 54, 558, 10.1016/0003-9861(55)90070-9 Baker, 1982, Treatment of homozygous familial hypercholesterolemia with probucol, S Afr Med J, 62, 7 Blankenhorn, 1987, Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts, JAMA, 257, 3233, 10.1001/jama.1987.03390230069027 Blum, 1976, Cholestyramine: An effective twice daily dosage regimen, Ann Intern Med, 85, 287, 10.7326/0003-4819-85-3-287 Canner, 1986, Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin, J Am Coll Cardiol, 8, 1245, 10.1016/S0735-1097(86)80293-5 Carmena, 1989, Treatment of heterozygous familial hypercholes terolemia with pravastatin (CS-514) and/or cholestyramine (The Spanish Multicenter Study), 757 Casdorph, 1975, The single dose method of administering cholestyramine, Angiology, 26, 671, 10.1177/000331977502600905 1978, Committee of Principal Investigators: A cooperative trial in the prevention of ischaemic heart disease using clofibrate, Br Heart J, 40, 1069, 10.1136/hrt.40.10.1069 1984, Committee of Principal Investigators: WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up, Lancet, ii, 600 1985, Consensus Conference: Lowering blood cholesterol to prevent heart disease, JAMA, 253, 2080, 10.1001/jama.1985.03350380096029 1975, Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease, JAMA, 231, 360, 10.1001/jama.1975.03240160024021 East, 1988, Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation, N Engl J Med, 318, 47, 10.1056/NEJM198801073180111 East, 1986, Preliminary report: Treatment of type III hyperlipoproteinemia with mevinolin, Metabolism, 35, 97, 10.1016/0026-0495(86)90106-X Endo, 1976, Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity, FEBS Lett, 72, 323, 10.1016/0014-5793(76)80996-9 Endo, 1976, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum, J Antibiot (Tokyo), 29, 1346, 10.7164/antibiotics.29.1346 1988, Expert Panel: Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults, Arch Intern Med, 148, 36, 10.1001/archinte.1988.00380010040006 Freeman, 1988, Intestinal HMG-CoA reductase activity is low in hypercholesterolemic patients and is further decreased with lovastatin therapy, J Lipid Res, 29, 839, 10.1016/S0022-2275(20)38478-9 Frick, 1987, Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia, N Engl J Med, 317, 1237, 10.1056/NEJM198711123172001 Garg, 1988, Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus, N Engl J Med, 318, 81, 10.1056/NEJM198801143180204 Ginsberg, 1987, Suppression of apolipoprotein B production during treatment of cholesterol storage disease with lovastatin: Implications for regulation of apolipoprotein B synthesis, J Clin Invest, 80, 1692, 10.1172/JCI113259 Gluek, 1983, Therapy of familial and acquired hyperlipoproteinemia in children and adoles cents, Prev Med, 12, 835, 10.1016/0091-7435(83)90266-9 Grundy, 1981, The influence of nicotinic acid on metabolism of cholesterol and triglycerides in man, J Lipid Res, 22, 24, 10.1016/S0022-2275(20)34737-4 Havel, 1987, Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: A multicenter study, Ann Intern Med, 107, 609, 10.7326/0003-4819-107-5-609 Hodges, 1982, Safety of gemfibrozil (Lopid) in clinical use, Res Clin Forum, 4, 37 Hunninghake, 1989, Drug therapy of hyperlipidemia, Cardiol Board Rev, 6, 39 Hunninghake, 1986, Resin therapy. Adverse effects and their management, 67 Hunninghake, 1980, Effect of probucol on plasma lipids and lipoproteins in type lib hyperlipoproteinemia, Atherosclerosis, 37, 469, 10.1016/0021-9150(80)90153-7 Hunninghake, 1987, Metabolic studies with lovastatin in patients with primary hypercholesterolemia, 150 Hunninghake, 1988, Lovastatin: Follow-up ophthalmologic data, JAMA, 259, 354, 10.1001/jama.1988.03720030022020 Hunninghake, 1987, Effect of fibric acid derivatives on blood lipid and lipoprotein levels, Am J Med, 83, 44, 10.1016/0002-9343(87)90870-9 Hunninghake, 1981, Effect of colestipol and clofibrate on plasma lipids and lipoproteins in type Ha hyperlipoproteinemia, Metabolism, 30, 605, 10.1016/0026-0495(81)90140-2 Illingworth, 1987, Lipid lowering drugs: An overview of indications and optimum therapeutic use, Drugs, 33, 259, 10.2165/00003495-198733030-00003 Illingworth, 1984, Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia, J Clin Invest, 74, 1972, 10.1172/JCI111618 Kirby, 1962, Cataract formation after triparanol therapy, Arch Ophthalmol, 68, 486, 10.1001/archopht.1962.00960030490010 Knopp, 1987, Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia, Am J Med, 83, 50, 10.1016/0002-9343(87)90871-0 Knopp, 1985, Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin, Metabolism, 34, 642, 10.1016/0026-0495(85)90092-7 Kovanen, 1981, Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog, Proc Natl Acad Sei USA, 78, 1194, 10.1073/pnas.78.2.1194 Linstedt, 1957, The formation of bile acids from 7-a-hydroxycholesterol in the rat, Acta Chem Scand, 11, 417, 10.3891/acta.chem.scand.11-0417 1984, Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results, 1. Reduction in incidence in coronary heart disease. JAMA, 251, 351 1984, Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results, 2. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA, 251, 365 1986, Lovastatin Study Group II: Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia, JAMA, 256, 2829, 10.1001/jama.1986.03380200067023 1988, Lovastatin Study Group III: A multicenter comparison of lovastatin and cholestyramine in the therapy of severe primary hypercholesterolemia, JAMA, 260, 359, 10.1001/jama.1988.03410030075032 Ma, 1986, Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits, Proc Natl Acad Sei USA, 83, 8370, 10.1073/pnas.83.21.8370 Manninen, 1988, Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study, JAMA, 260, 641, 10.1001/jama.1988.03410050061031 Mellies, 1980, Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoprotein Al and A2 in adults with primary familial hypercholesterolemia, Metabolism, 29, 956, 10.1016/0026-0495(80)90039-6 Miettinen, 1981, Effect of probucol on the activity of postheparin plasma lipoprotein lipase and hepatic lipase, Clin Chim Acta, 113, 59, 10.1016/0009-8981(81)90440-X Mol, 1986, Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia, Lancet, 2, 936, 10.1016/S0140-6736(86)90598-2 Mullin, 1989, Fulminant hepatic failure after ingestion of sustained-release nicotinic acid, Ann Intern Med, 111, 253, 10.7326/0003-4819-111-3-253 1984, National Heart, Lung, and Blood Institute Consensus Development Panel: Treatment of hypertriglyceridemia, JAMA, 251, 1196, 10.1001/jama.1984.03340330054025 Norman, 1988, Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin, N Engl J Med, 318, 46, 10.1056/NEJM198801073180110 Olsson, 1983, Prostacyclin production augmented in the short term by nicotinic acid, Lancet, 2, 565, 10.1016/S0140-6736(83)90588-3 Parker, 1984, Plasma mevalonate as a measure of cholesterol synthesis in man, J Clin Invest, 74, 795, 10.1172/JCI111495 Peters, 1985, Effect of time of administration of cholestyramine on plasma lipids and lipoproteins, Artery, 13, 1 Pietro, 1989, Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II), Am J Cardiol, 63, 682, 10.1016/0002-9149(89)90251-8 Shepherd, 1986, An overview of the effects of p-chlorphenoxyisobutyric acid derivatives on lipoprotein metabolism, 135 Shepherd, 1980, Cholestyramine promotes receptor mediated low density lipoprotein catabolism, N Engl J Med, 302, 1219, 10.1056/NEJM198005293022202 Steinberg, 1986, Studies on the mechanism of action of probucol, Am J Cardiol, 57, 16H, 10.1016/0002-9149(86)90430-3 Steinberg, 1988, In vivo inhibition of foam cell development by probucol in Watanabe rabbits, Am J Cardiol, 62, 6B, 10.1016/S0002-9149(88)80044-4 1987, Study Group of the European Atherosclerosis Society: Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society, Eur Heart J, 8, 77 Tobert, 1988, Efficacy and long-term adverse effect pattern of lovastatin, Am J Cardiol, 62, 28J, 10.1016/0002-9149(88)90004-5 Tsujita, 1986, CS-514, a competitive inhibitor of 3-hydroxy-3-methylglytaryl-coenzyme A reductase: Tissue selective inhibitor of sterol synthesis and hypolipidemic effect on various animal species, Biochim Biophys Acta, 877, 50, 10.1016/0005-2760(86)90117-7 Walldius, 1988, Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/ placebo: Probucol Quantitative Regression Swedish Trial (PQRST): A status report, Am J Cardiol, 62, 37B, 10.1016/S0002-9149(88)80049-3 Witztum, 1979, Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins, Metabolism, 28, 221, 10.1016/0026-0495(79)90067-2 Yamamoto, 1986, Effects of probucol on xanthoma regression in familial hypercholesterolemia, Am J Cardiol, 57, 29H, 10.1016/0002-9149(86)90434-0